Foundayo just became the first GLP-1 pill with no food restrictions. FDA approved April 2026. Learn more →
✓ FDA Approved ⭐ Nov 2023 GLP-1/GIP · Eli Lilly

Zepbound

Tirzepatide · Approved November 2023

The most powerful weight loss shot FDA approved today. Zepbound targets two hunger hormones instead of one, and in a head to head trial it outperformed Wegovy by nearly 50% more weight loss. Also approved to treat sleep apnea in people with obesity.

💉
At a Glance

Everything You Need to Know

Avg. Weight Loss
21%
Up to 22.5% at highest dose
Form & Schedule
Weekly Shot
Self injected once per week
Food Restriction
None
Take any time, with or without food
Active Ingredient
Tirzepatide
Dual GLP-1 & GIP agonist
Manufacturer
Eli Lilly
Same maker as Foundayo & Mounjaro
FDA Status
✅ Approved
Weight management & sleep apnea
Plain English

What Exactly Is Zepbound?

A once weekly injection that targets two hunger hormones at once.Zepbound is a once weekly injection that works on two hunger regulating hormones at the same time, making it uniquely powerful for weight loss.

While most GLP-1 medications only target one hunger hormone (GLP-1), Zepbound (tirzepatide) targets two: GLP-1 and GIP. GIP is another gut hormone that works alongside GLP-1 to regulate appetite and metabolism. Together, they create a stronger hunger suppressing effect than either hormone alone. This is why Zepbound consistently outperforms semaglutide based medications in direct trial comparisons.

Zepbound is the weight loss approved version of Mounjaro, Eli Lilly's diabetes medication. Both contain the same active ingredient at the same doses.

The Science, Simply

How Zepbound Works

Targeting two hormones at once is what makes Zepbound so effective.Zepbound attacks hunger from two angles simultaneously, which is why its results are stronger than single hormone GLP-1 drugs.

1

Activates GLP-1 Receptors

Like Wegovy and other GLP-1 drugs, tirzepatide activates GLP-1 receptors in the brain and gut. This signals fullness, slows digestion, and reduces your appetite after meals.

2

Also Activates GIP Receptors

GIP is a second hormone released after eating. Tirzepatide also binds to GIP receptors, amplifying the appetite suppressing effect and improving how the body processes fat. This dual action is what sets Zepbound apart.

3

Stronger Hunger Suppression

The combined effect of activating both hormones produces more powerful hunger reduction than GLP-1 alone. Clinical trials show meaningfully higher weight loss compared to semaglutide at equivalent doses.

Clinical Trial Data

What the Trials Showed

From the SURMOUNT-1 trial: the strongest results ever recorded at approval.Zepbound's results in the SURMOUNT-1 trial were the strongest ever recorded for an FDA approved weight loss medication at the time of its approval.

21%
Average Body Weight Lost
Up to 22.5% at highest dose (15mg)
1 in 2
Lost 20% or More
At the highest dose in SURMOUNT-1
52 lbs
Average Pounds Lost
For a 250 lb person at highest dose
ℹ️ Individual results vary. Doses start low (2.5 mg) and increase gradually over 20 weeks to the target dose. Trial participants followed a reduced calorie diet and increased physical activity. Most results seen between weeks 52-72.

"I have patients who did fine on semaglutide and patients who did nothing on it. The ones who switched to tirzepatide and suddenly started losing again, I don't have a clean explanation for all of them. But it happens enough that I pay attention to it."

Dr. Quoc N. Dang, DO

Dr. Quoc N. Dang, DO

Bariatric Surgeon · Obesity Medicine

Eligibility

Is Zepbound Right for You?

Prescription only. For adults with obesity or a weight related condition.Zepbound requires a prescription and is intended for adults with obesity or overweight with a weight related health condition.

✅ Good Candidates

  • BMI of 30 or higher (clinically obese)
  • BMI of 27+ with a weight related condition (high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea)
  • Adults with moderate to severe obstructive sleep apnea and obesity. Zepbound became the first FDA approved medication for this indication in December 2024
  • Adults who want the highest efficacy FDA approved option available
  • People who have tried GLP-1 medications but want stronger results
  • Those comfortable with a weekly self injection

⚠️ May Not Be Right If...

  • You have a personal or family history of thyroid cancer (MTC)
  • You have Multiple Endocrine Neoplasia syndrome type 2
  • You're pregnant, planning to become pregnant, or breastfeeding
  • You have a history of pancreatitis
  • You're already on another GLP-1 or GIP medication

⚕️Always consult your doctor before starting any weight loss medication.

What to Expect

Side Effects

Mostly GI related and short lived. A slow ramp over 20 weeks helps a lot.Side effects are similar to other GLP-1 medications and are mostly gastrointestinal. Zepbound uses a gradual dose escalation schedule over 20 weeks to minimize early symptoms.

Common Side Effects

Usually mild to moderate · Often improve over time
  • Nausea31%
  • Diarrhea23%
  • Vomiting20%
  • Constipation17%
  • Stomach pain10%
  • Injection site reaction7%

Serious (Rare) Side Effects

Uncommon · Contact your doctor immediately
  • Severe abdominal pain (possible pancreatitis)
  • Thyroid tumors (based on animal studies)
  • Gallbladder disease (gallstones)
  • Kidney problems (often from dehydration)
  • Serious allergic reaction
Pricing & Access

What Does Zepbound Cost?

More affordable via LillyDirect, especially with single dose vials.Zepbound is one of the more affordable weight loss injections when accessed through Eli Lilly's direct program, especially with single dose vials.

Self Pay via LillyDirect

$299-$449/mo
Through LillyDirect. Starting dose (2.5mg) as low as $299/mo. Higher maintenance doses up to $449/mo.

With Commercial Insurance

As low as $25/mo
Eli Lilly's savings card for eligible commercially insured patients. Most people with coverage pay $25-$50/month.

Medicare / Medicaid

Varies
Coverage expanding under recent legislation. Check with your plan directly, as coverage varies by state and plan type.
💡 Tip: LillyDirect offers Zepbound single dose vials at lower self pay prices than the auto injector pens. In February 2026, Eli Lilly also launched the Zepbound KwikPen, a four dose monthly pen starting at $299/month, offering another convenient self pay option. Ask your doctor which format makes the most sense for you. Thinking about switching from Zepbound to a pill? See our step by step guide.
Side by Side

Zepbound vs. Other Options

Zepbound vs. the other leading weight loss medications.How does Zepbound stack up against the other leading weight loss medications?

Medication Avg. Weight Loss Form Targets Approved For
💉Zepbound You're here 21% Weekly Injection GLP-1 + GIP Weight Loss
💉Wegovy 15% Weekly Injection GLP-1 only Weight Loss
💊Foundayo 9-15% Daily Pill GLP-1 only Weight Loss
💊Oral Wegovy 15% Daily Pill GLP-1 only Weight Loss
Common Questions

Frequently Asked Questions

Both contain the same active ingredient, tirzepatide, at the same doses. The difference is purely in their approved use: Mounjaro is FDA approved for type 2 diabetes, while Zepbound is FDA approved for chronic weight management. Because they're chemically identical, some doctors prescribe Mounjaro off-label for weight loss, though Zepbound is the on label choice.
Yes. In the SURMOUNT-5 head to head trial (72 weeks), people on Zepbound lost an average of 20.2% of body weight (about 47 lbs) compared to 13.7% (about 33 lbs) on Wegovy. That's a meaningful difference, roughly 14 more pounds on average. Both are effective, and the best choice depends on your individual situation, insurance coverage, and tolerance for side effects.
Yes. In December 2024, the FDA approved Zepbound as the first and only prescription medication for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. In clinical trials, people using Zepbound had 25–29 fewer breathing interruptions per hour compared to 5–6 fewer with placebo. This makes Zepbound the only weight loss medication with a dedicated FDA approval for sleep apnea.
Most people notice reduced appetite within the first 1 to 2 weeks, even at the starting dose of 2.5 mg. Meaningful weight loss typically becomes visible between weeks 4 and 12. The full escalation to the highest dose takes 20 weeks, and most significant weight loss occurs between weeks 20 and 72. Consistency is key.
Yes. Eli Lilly offers Zepbound in single dose vials through LillyDirect, which tend to be cheaper than the auto injector pens when paying out of pocket. You draw the dose into a small insulin syringe and inject it yourself. The process is straightforward, but requires comfort with a traditional needle. Ask your doctor if this option makes sense for your situation.
Yes, in most cases. Studies show that the majority of people regain a significant portion of lost weight within one to two years of stopping. This is consistent across all GLP-1 and dual agonist medications and is not unique to Zepbound. Many doctors treat these medications as long term therapies, similar to how blood pressure medications are managed. Discuss a long term plan with your doctor before starting.
Dr. Quoc N. Dang, DO
Medically Reviewed by
Dr. Quoc N. Dang, DO
Bariatric Surgeon